

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
05 December 2024 (05.12.2024)



(10) International Publication Number
WO 2024/246717 A1

- (51) **International Patent Classification:**
C07F 9/655 (2006.01) *A61P 35/00* (2006.01)
- (21) **International Application Number:**
PCT/IB2024/055121
- (22) **International Filing Date:**
26 May 2024 (26.05.2024)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/469,115 26 May 2023 (26.05.2023) US
- (71) **Applicant:** **LUNELLA BIOTECH, INC.** [CA/CA]; 145 Richmond Road, Ottawa, Ontario K1Z 1A1 (CA).
- (72) **Inventors:** **LISANTI, Michael P.**; c/o Lunella Biotech, Inc., 145 Richmond Road, Ottawa, Ontario K1Z 1A1 (CA). **SOTGIA, Federica**; c/o Lunella Biotech, Inc., 145 Richmond Road, Ottawa, Ontario K1Z 1A1 (CA). **DI PISA, Filippo**; c/o Lunella Biotech, Inc., Ottawa, Ontario K1Z 1A1 (CA). **KANGASMETSA, Jussi**; c/o Lunella Biotech, Inc., Ottawa, Ontario K1Z 1A1 (CA).
- (81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,

KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

- (84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report (Art. 21(3))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(54) **Title:** MITOCHONDRIA SPECIFIC TRANSCRIPTION INHIBITORS



(57) **Abstract:** Mitochondria specific transcription inhibitors may be used to target and eliminate cancer stem cells, and may be used as therapeutic agents for the treatment of cancer, including reducing the likelihood of and/or preventing tumor recurrence and metastasis. The mitochondria specific transcription inhibitor compounds disclosed herein have demonstrated inhibition of tumorsphere forming capacity, migration and stemness-related signaling in cancer stem cells. These properties result from selective inhibiting of mitochondrial transcription targeting mitochondrial RNA polymerase (POLRMT) in cancer cells. (Formula A)

WO 2024/246717 A1